CBD Life Sciences Inc. CBDL
The SEC does not publish structured financial data (XBRL) for CBD Life Sciences Inc., so there are no statement tables here.
This is common for foreign companies that trade over the counter and for filers that only submit documents.
Its filings are still listed below and on SEC EDGAR.
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| QUALIF | Filing | Jun 8, 2026 | — |
| CORRESP | Letter to the SEC | Jun 4, 2026 | — |
| UPLOAD | Letter from the SEC | May 21, 2026 | — |
| 1-A | Filing | May 15, 2026 | — |
| 253G2 | Form 253g2 | May 19, 2025 | — |
| QUALIF | Filing | Mar 19, 2025 | — |
| CORRESP | Letter to the SEC | Mar 18, 2025 | — |
| CORRESP | Letter to the SEC | Mar 17, 2025 | — |
| 1-A POS | Filing | Mar 17, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 17, 2025 | — |
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- CBDL (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Scottsdale, AZ
- SEC CIK
- 1776073
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.